Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- 3 Top-Ranked Consumer ETFs to Buy Now
- Top Stocks with Big Potential Catch-Up Moves
- Roundtable Top Picks of the Week
- Anatomy of Success: Green Mountain Coffee
- The Mega-Rally Rolls On
- RTI: Prediction Contest: S&P 500 on Dec. 31st
- Industry Rank Analysis: Shifting Into Overdrive
- Biotechnology ETF Investing 101
- 3 Dividend Stocks at Reasonable Prices
- Options Strategies & the Zacks Rank
- AWS 5/21: The Beginning of the End for QE
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/21/2013
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| SUMMER INFAN | SUMR | 6.63% |
| RADIANT LOGI | RLGT | 6.38% |
| FEDERAL MOGU | FDML | 5.69% |
| NATUS MEDICA | BABY | 5.34% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Hospira Inc.’s ( HSP - Analyst Report ) second-quarter 2012 earnings (excluding special items) of 51 cents per share beat the Zacks Consensus Estimate of 49 cents. However, earnings fell short of the year-ago figure by 45.7%.
The reported quarter’s earnings were hurt by lower revenues and higher costs. On a reported basis (including special items), the company suffered a loss of 2 cents per share as opposed to the year-ago earnings of 85 cents.
The Lake Forest, Illinois-based company came up with revenues of $1.0 billion in the reported quarter, beating the Zacks Consensus Estimate of $986 million. Revenues were, however, 2.9% lower than the year-ago figure due to adverse foreign currency movements and the slowdown in production at the company’s facility in Rocky Mountain, North Carolina.
Quarter in Details
The Specialty Injectable Pharmaceuticals (SIP) business, the biggest contributor to Hospira’s revenues, performed disappointingly in the quarter with sales from the segment declining 4.6% (down 1.7% at constant currency) to $644.2 million. This segment includes generic injectables as well as proprietary specialty injectables. The SIP unit includes drugs such as the generic version of Sanofi’s ( SNY - Analyst Report ) oncology therapy Taxotere.
Sales in the Medication Management (MMS) segment climbed 3.5% (up 5.7% at constant currency) to $255.1 million. Sales in the Other Pharma division declined 5.9% (down 4.4% at constant currency) to $134.0 million.
Geographically, the Americas, Europe, Middle East and Africa (EMEA) and the Asia-Pacific (APAC) markets contributed $810.3 million (down 2.9% at constant currency), $135.3 million (up 11.0% at constant currency) and $87.7 million (up 6.5% at constant currency), respectively, to total revenue in the reported quarter.
2012 Outlook
The company continues to expect top-line growth in the range of -1% to 2% on a constant currency basis. Foreign exchange is expected to negatively impact the top line by 1 to 2%. The company expects 2012 adjusted earnings at the low end of the projected range of $2.00–$2.30 per share. The Zacks Consensus Estimate for 2012 currently stands at $2.11 per share.
Hospira now expects cash flow from operations in the range of $475-$525 million (previous guidance: $575-$625 million) in 2012. The company continues to expect capital expenditures in the range of $350-$400 million. Depreciation and amortization continues to be projected in the range of $240-$260 million.
Our Recommendation
We currently have a Neutral recommendation on Hospira. The stock carries a Zacks #4 Rank (Sell rating) in the short run.
Read the full Analyst Report on HSP
Read the full Analyst Report on SNY